Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GRI Bio, Inc.GRI · Entity 8336 | Director | September 18, 2025 | September 22, 2025 |
| SPRUCE BIOSCIENCES, INC.SPRB · Entity 6471 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GRI Bio, Inc.
Report date September 18, 2025 · Filed September 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.93 · Expires 2035-09-18 | Direct | 23,605 |
Reported balance
After 2025-09-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-18 · Grant · Acquired 23,605 · Balance 23,605 F1: Options to purchase 17,621 shares vested in full upon the date of grant and options to purchase 5,984 shares will vest in four substantially equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase 17,621 shares vested in full upon the date of grant and options to purchase 5,984 shares will vest in four substantially equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant.
SPRUCE BIOSCIENCES, INC.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.70 · Expires 2036-05-20 | Direct | 1,700 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 1,700 · Balance 1,700 F1: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 26, 2026 20:30 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 1,700 | $0.00 Strike: $52.70 | $0.00 |
DisclosureSEC source: 0001822557-26-000002 · form4-05262026_040508.xml · derivative · entry 1 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,700 Underlying: Common Stock · 1,700 shares Expires 2036-05-20 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:50 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Disposition to issuerStock Option (Right to Buy) · Derivative | 400 | Not disclosed Strike: $169.50 | Not disclosed |
DisclosureSEC source: 0001822557-25-000007 · form4-12152025_111206.xml · derivative · entry 10 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400 shares Expires 2033-05-24 F1 · derivative.exercise_price: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:50 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 400 | Not disclosed Strike: $104.13 | Not disclosed |
DisclosureSEC source: 0001822557-25-000007 · form4-12152025_111206.xml · derivative · entry 9 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400 Underlying: Common Stock · 400 shares Expires 2033-05-24 F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:50 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Disposition to issuerStock Option (right to buy) · Derivative | 133 | Not disclosed Strike: $1,143.00 | Not disclosed |
DisclosureSEC source: 0001822557-25-000007 · form4-12152025_111206.xml · derivative · entry 8 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 133 shares Expires 2031-05-19 F1 · derivative.exercise_price: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:50 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (right to buy) · Derivative | 133 | Not disclosed Strike: $104.13 | Not disclosed |
DisclosureSEC source: 0001822557-25-000007 · form4-12152025_111206.xml · derivative · entry 7 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133 Underlying: Common Stock · 133 shares Expires 2031-05-19 F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:50 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Disposition to issuerStock Option (Right to Buy) · Derivative | 362 | Not disclosed Strike: $230.25 | Not disclosed |
DisclosureSEC source: 0001822557-25-000007 · form4-12152025_111206.xml · derivative · entry 6 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 362 shares Expires 2030-08-06 F1 · derivative.exercise_price: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:50 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 362 | Not disclosed Strike: $104.13 | Not disclosed |
DisclosureSEC source: 0001822557-25-000007 · form4-12152025_111206.xml · derivative · entry 5 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 362 Underlying: Common Stock · 362 shares Expires 2030-08-06 F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:50 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Disposition to issuerStock Option (Right to Buy) · Derivative | 309 | Not disclosed Strike: $123.00 | Not disclosed |
DisclosureSEC source: 0001822557-25-000007 · form4-12152025_111206.xml · derivative · entry 4 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 309 shares Expires 2030-06-07 F1 · derivative.exercise_price: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:50 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 309 | Not disclosed Strike: $104.13 | Not disclosed |
DisclosureSEC source: 0001822557-25-000007 · form4-12152025_111206.xml · derivative · entry 3 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 309 Underlying: Common Stock · 309 shares Expires 2030-06-07 F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:50 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Disposition to issuerStock Option (Right to Buy) · Derivative | 173 | Not disclosed Strike: $108.00 | Not disclosed |
DisclosureSEC source: 0001822557-25-000007 · form4-12152025_111206.xml · derivative · entry 2 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 173 shares Expires 2029-07-22 F1 · derivative.exercise_price: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:50 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 173 | Not disclosed Strike: $104.13 | Not disclosed |
DisclosureSEC source: 0001822557-25-000007 · form4-12152025_111206.xml · derivative · entry 1 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173 Underlying: Common Stock · 173 shares Expires 2029-07-22 F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 20:05 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 23,605 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001822557-25-000005 · wk-form4_1758571550.xml · derivative · entry 1 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,605 Underlying: Common Stock · 23,605 shares Expires 2035-09-18 F1 · derivative.exercise_date: Options to purchase 17,621 shares vested in full upon the date of grant and options to purchase 5,984 shares will vest in four substantially equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant. Read SEC document |
| August 26, 2025 Filed Aug 27, 2025 12:24 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 5,994 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001824293-25-000139 · wk-form4_1756297487.xml · derivative · entry 1 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,994 Underlying: Common Stock · 5,994 shares Expires 2035-08-26 F1 · derivative.exercise_date: Options to purchase 4,044 shares vested in full upon the date of grant and options to purchase 1,950 shares will vest in four substantially equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant. Read SEC document |
| August 13, 2025 Filed Aug 14, 2025 20:58 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 4,527 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001824293-25-000119 · wk-form4_1755205119.xml · derivative · entry 1 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,527 Underlying: Common Stock · 4,527 shares Expires 2035-08-13 F1 · derivative.exercise_date: The stock option vests in 4 equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 23:38 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001415889-25-020269 · form4-07242025_110757.xml · derivative · entry 1 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-07-21 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2026 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 22:57 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 30,297 | $0.69 Strike: $0.69 | $20,774.65 |
DisclosureSEC source: 0001824293-25-000032 · wk-form4_1737759469.xml · derivative · entry 1 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,297 Underlying: Common Stock · 30,297 shares Expires 2035-01-23 Read SEC document |
| May 22, 2024 Filed May 24, 2024 20:27 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001415889-24-014492 · form4-05242024_080514.xml · derivative · entry 1 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-21 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2025 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 20:07 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 34,483 | $2.90 Strike: $2.90 | $100,000.70 |
DisclosureSEC source: 0001824293-23-000154 · wk-form4_1692043648.xml · derivative · entry 1 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,483 Underlying: Common Stock · 34,483 shares Expires 2033-08-10 F1 · derivative.exercise_date: Vests as to 1/12th of the underlying shares of common stock on the date of grant, then in 11 equal quarterly installments such that the stock option is fully vested on the third annual anniversary of the date of grant. Read SEC document |
| May 25, 2023 Filed May 26, 2023 21:39 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.26 | $0.00 |
DisclosureSEC source: 0001209191-23-032661 · doc4.xml · derivative · entry 1 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-24 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2024 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:06 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001209191-22-032493 · doc4.xml · derivative · entry 1 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2032-05-24 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2023 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| May 20, 2021 Filed May 22, 2021 01:10 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $15.24 | $0.00 |
DisclosureSEC source: 0001209191-21-035151 · doc4.xml · derivative · entry 4 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-05-19 F3 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2022 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| May 20, 2021 Filed May 22, 2021 01:10 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionStock Option (Right to Buy) · Derivative | 334 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001209191-21-035151 · doc4.xml · derivative · entry 3 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,673 Underlying: Common Stock · 2,007 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the stock option vest over a four-year period commencing October 19, 2017, with 1/4th of the shares vesting on October 19, 2018 and 1/36th of the remaining shares vesting on a monthly basis. Read SEC document |
| May 20, 2021 Filed May 22, 2021 01:10 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | SaleCommon Stock | 334 | $15.29 | $5,106.86 |
DisclosureSEC source: 0001209191-21-035151 · doc4.xml · nonDerivative · entry 2 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| May 20, 2021 Filed May 22, 2021 01:10 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 334 | $0.85 | $283.90 |
DisclosureSEC source: 0001209191-21-035151 · doc4.xml · nonDerivative · entry 1 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2021 Filed May 5, 2021 01:09 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,045 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001209191-21-030171 · doc4.xml · derivative · entry 3 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,007 Underlying: Common Stock · 16,052 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the stock option vest over a four-year period commencing October 19, 2017, with 1/4th of the shares vesting on October 19, 2018 and 1/36th of the remaining shares vesting on a monthly basis. Read SEC document |
| April 30, 2021 Filed May 5, 2021 01:09 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | SaleCommon Stock | 14,045 | $16.14 | $226,663.83 |
DisclosureSEC source: 0001209191-21-030171 · doc4.xml · nonDerivative · entry 2 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents a weighted-average sales price per share. These shares were sold in multiple transactions at prices ranging from $15.64 to $17.09. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 30, 2021 Filed May 5, 2021 01:09 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 14,045 | $0.85 | $11,938.25 |
DisclosureSEC source: 0001209191-21-030171 · doc4.xml · nonDerivative · entry 1 SIMPSON CAMILLA V · CIK 0001822557 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.